Novartis and Vectura reveal positive Phase III data for combination COPD drug
This article was originally published in Scrip
Executive Summary
Novartis and Vectura are progressing towards a regulatory submission for QVA149, an investigational treatment for chronic obstructive pulmonary disease (COPD), having announced that the first three studies in the Phase III IGNITE programme have all met their primary endpoints in efficacy, safety and exercise endurance.